SUBSCRIBE
SUBSCRIBE

Biogen

NEWS
Deals
Amgen, Biogen, Celgene Eye M&A In Trump’s “Pro-Biotech” World
November 29, 2016
 · 
1 min read
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Drug Development
Investors Remain Bullish Over Biogen’s Risky Alzheimer’s Drug Despite Eli Lilly Setback
November 28, 2016
 · 
4 min read
Business
Biogen Alum Put in Charge of Raising Bain Capital’s First Life Science Investment Fund
November 23, 2016
 · 
1 min read
Genetown
Biogen’s Tecfidera was the Most Successful Drug Approved in 2013, But Other Mass. Biotechs Didn’t Do So Well
November 17, 2016
 · 
1 min read
How Biogen Makes Most of Its Cash
Business
Biogen Taps Former Spark Therapeutics Exec and a Finance Vet for Hemophilia Spin-off Company Bioverativ
November 15, 2016
 · 
3 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Drug Development
3 Reasons That Make Biogen the King of a Crumbling Empire
November 11, 2016
 · 
2 min read
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Drug Development
The Small-Cap Biotech That Could Take Down Biogen, Celgene, Eli Lilly and Gilead in Alzheimer’s
November 9, 2016
 · 
2 min read
MaxWell Biosciences CEO Faces Backlash After Openly Discriminating Against Men
Drug Development
Stocks Rocket as Biogen, Ionis Pharma Halt Study on Positive Phase III
November 7, 2016
 · 
2 min read
Why Merck and Allergen Won’t Buy Biogen
Deals
Why Merck & Co. and Allergan Won’t Buy Biogen
November 4, 2016
 · 
4 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
JOBS
IN THE PRESS
Press Releases
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
December 23, 2025
 · 
13 min read
Press Releases
Canadian HTA Assessments Recognize Therapeutic Value of QALSODY™ (tofersen injection) and its Potential to Modify Disease Progression in Individuals Living with SOD1-ALS
December 11, 2025
 · 
6 min read
Press Releases
Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada
December 10, 2025
 · 
8 min read
Press Releases
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
December 9, 2025
 · 
11 min read
Press Releases
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 8, 2025
 · 
19 min read
Press Releases
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 8, 2025
 · 
19 min read
Press Releases
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
December 4, 2025
 · 
24 min read
Press Releases
New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
December 3, 2025
 · 
21 min read
Press Releases
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
December 2, 2025
 · 
16 min read
Press Releases
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
December 2, 2025
 · 
16 min read
Load More